Administration of Angiotensin-Converting Enzyme Inhibitors and <i>β</i>-Blockers During Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?

Stefano Oliva, Giovanni Cioffi, Silvia Frattini et al.|The Oncologist|2012

Cited by 49